HER-2/neu

摘要： 目的 探讨巨大囊肿病液体蛋白-15(GCDFP-15)、雌激素受体(ER)、孕激素受体(PR)、原癌基因C-erbB-2、原癌基因Her2/Neu表达与乳腺癌超声征象的关系.方法 选取乳腺癌患者100例,术前行乳腺彩超检查,术后应用免疫组化法检测乳腺癌组织标本中GCDFP-15、ER、PR、C-erbB-2、Her2/Neu的表达情况.结果 GCDFP-15蛋白阴性率为61.00％,ER为50.00％,PR为36.00％,C-erbB-2为62.00％,Her2/Neu为45.00％.有内部微小钙化、血流显像分级2～3级、淋巴结转移的乳腺癌患者GCDFP-15阴性率明显高于无内部微小钙化、血流显像分级0～1级、无淋巴结转移的患者,差异具有统计学意义(P<0.01).有边缘毛刺征和周围高回声晕象的乳腺癌患者ER、PR阳性率明显高于无边缘毛刺征和周围高回声晕象的患者,差异具有统计学意义(P<0.01);有淋巴结转移的乳腺癌患者ER、PR阳性率明显低于无淋巴结转移的患者,差异具有统计学意义(P<0.01).Her2/Neu阳性率明显高于无内部微小钙化、血流显像分级0～1级、无淋巴结转移的患者,差异具有统计学意义(P<0.05).结论 乳腺癌组织中GCDFP-15、ER、PR、C-erbB-2、Her2/Neu表达与超声征象密切相关,可用于乳腺癌患者的预后评估.

摘要： 原癌基因HER-2/neu(human epidermal growth factor receptor type 2)在乳腺癌(20%~40%)、结直肠癌(54%~100%)、卵巢癌(25%)等多种肿瘤中有扩增或过表达,故HER-2/neu蛋白是肿瘤候选靶标抗原之一,且已被证明具有开发抗乳腺癌疫苗的潜力。目前针对不同类型的HER-2疫苗,包括全细胞疫苗、全序列蛋白疫苗、肽疫苗、树突状细胞(DC)相关疫苗以及基因疫苗等展开了一系列研究,并取得一定进展。该文通过检索百度学术,PubMed,Springer以及ScienceDirect数据库,对近年来HER-2/neu肿瘤疫苗的制备及其抗肿瘤活性机制的研究进展进行综述。HER-2/neu肿瘤疫苗经抗原递呈细胞(APCs)展示,能够有效地激活CD4^+T和CD8^+T,并诱导特异性抗肿瘤免疫应答反应,其结构及组成佐剂的改变、融合表达以及DC诱导等疫苗设计工艺改变,能够显著地提高疫苗的免疫活性和抗肿瘤活性。HER-2疫苗在临床试验研究中发现能够有效地降低抗体药物治疗所致的耐药性,反复用药以及其它化疗药物的严重毒副作用等缺陷,并有效稳定地发挥抗肿瘤活性,为肿瘤的治疗提供一个崭新的视角。

摘要： 目的:探索蛇床子素对具有HER-2/neu高表达的人乳腺癌SK-BR-3和MDA-MB-231细胞系中的促血管生成因子的表达影响,并阐述其可能的活性机制。方法:以蛇床子素与表皮生长因子(EGF)对具有HER-2/neu高表达的人乳腺癌SK-BR-3和MDA-MB-231细胞系进行单独或联合处理,用酶联免疫吸附测定法(ELISA)定量测定肿瘤细胞促血管生成因子(VEGF、MMP-9)的表达,Western blot检测HER-2/neu及MAPK信号通路关键蛋白ERK1/2的磷酸化水平改变,QRT-PCR检测VEGF、MMP-9在m RNA水平的变化。结果:蛇床子素对HER-2/neu高表达的人乳腺癌SK-BR-3和MDA-MB-231细胞系均具有显著的增殖抑制作用。EGF能显著促进HER-2/neu高表达的人乳腺癌SK-BR-3和MDA-MB-231细胞系表达肿瘤促血管生成因子,蛇床子素能显著能显著抑制ERK1/2蛋白的磷酸化,下调经EGF处理后肿瘤促血管生成因子(VEGF、MMP-9)的表达,并在m RNA水平显著抑制促血管生成因子的表达。结论:蛇床子素可能通过抑制HER-2/neu活性而阻断其下游的MAPK信号通路,通过抑制了ERK的磷酸化减少了MMP-9的表达,从而抑制乳腺癌细胞分泌VEGF,实现其对促血管生成因子表达水平的抑制作用。

摘要： Introduction: Screening mammography has led to a marked increase in detection of in situ breast tumors in the United States. The University of Southern California/Van Nuys Prognostic Index (USC/VNPI) predicts the recurrence rates of ductal carcinoma in situ (DCIS);however variations in tumor characteristics, USC/VNPI scores, receptor and human epithelial growth factor receptor (HER)-2/neu status across different ethnicities/races have not been well studied. This study aimed to evaluate the racial trends in incidence, patient demographics, tumor characteristics and treatment variations for patients with DCIS at a high volume teaching hospital. Methods: 395 women underwent surgical intervention for DCIS between 2000 and 2011. Their race/ethnicity was divided into five mutually exclusive categories and demographic and clinicopathological data was collected. Multivariate analysis was performed to evaluate variations in patient and tumor factors with respect to age, size and surgical management among different ethnicities and races. Results: 82.1% of Caucasian women underwent simple mastectomy with sentinel lymph node biopsy (SLNB) while lumpectomy with SLNB was highest in Hispanics (40%, p = 0.005). Overall, there was no significant difference in the incidence of receptor or HER-2/neu positivity, multicentricity, necrosis or grade of DCIS in the various racial groups, but there was a significant racial difference in the USC/VNPI scores (p < 0.001). Conclusion: On a community level, screening detected DCIS accounted for the vast majority of DCIS diagnosed, which reflected national trends. Although no racial variation in DCIS with respect to patient or tumor characteristics was observed, a racial difference in USC/VNPI score was identified among the Hispanic population. Additional studies are required to validate the significance of these findings.

摘要： Introduction-Breast cancer is the most common cancer and leading cause of death in women. In India, its incidence is rapidly rising over last few decades. Present study is aimed to study the pattern of expression of hormonal receptors and Her-2/neu in invasive breast carcinoma and to correlate estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu expressions with various clinicopathological parameters. Material and methods: The present study was carried out in Department of Pathology, S.C.B. Medical College, Cuttack in the year 2013 taking consecutive 100 cases. Routine H&E staining for histological diagnosis and IHC analysis for ER, PR and Her 2/neu was carried out in all 100 cases of breast malignancies. Results: 99% of cases are invasive breast carcinoma, not otherwise specify (IDC-NOS). The age ranges from 23 years to 72 years. Majority of tumors are of grade 2 (70%) followed by grade 3 (30%). ER PR and Her-2/neu expression are seen in 45%, 35% and 30% respectively. Triple negative cases comprise 35%. Higher number of grade 2 tumor shows ER, PR positivity as compared to grade 3 tumors. Her-2/neu expression does not show any significant correlation with age or lymph node status of the patient. Conclusion: ER and PR expression in breast cancers in the current study are found to be comparable to the findings of other authors, but the frequency of HER-2/neu expression is slightly higher. Significant correlation is observed between hormonal receptor status and the grade of the tumor. Inverse relationship is found between Her-2/neu expression and ER, PR receptor status. Her-2/neu expression is increased with size and high grade of tumor.

摘要： Objective: HER-2/neu status in gastric carcinomas (GCs) has not been studied before in the Egyptian population. Materials and Methods: Seventy-three GCs were evaluated for the expression of HER-2/neu and Ki-67 using immunohistochemistry (IHC). Fluorescence in situ Hybridization (FISH) was done for HER2/neu IHC score 2+ cases. Results: Out of the 73 gastric carcinomas, 23 (31.5%) were score 0, 17 (23.3%) were score 1+, 23 (31.5%) were score 2+, and 10 (13.7%) were score 3+. FISH analysis revealed that the HER-2/neu gene was amplified in 11 out of the 23 cases (47.8%) scored 2+ by IHC. Therefore, the overall HER-2/neu positivity rate was 28.8% and it was significantly associated with higher T-stage and lymphovascular invasion (LVI). The Ki-67 expression rate ranged between 10% and 100%, with 84.9% of the cases (n = 62) featuring high Ki-67 scores. High Ki-67 score was significantly associated with male sex, tumor grade, and number of positive nodes. HER-2/neu protein expression correlated significantly with Ki-67 score. Twenty tumors showed combined HER-2/neu positivity and high Ki-67 score and were significantly associated with higher T-stage and occurrence of LVI, implying a more aggressive behavior. Conclusions: The rate of HER-2/neu positive GCs in our series simulates universal rates, thereby mandating routine evaluation of HER-2/neu status in all GCs submitted to our laboratory to benefit from trastuzumab therapy. Further studies on a larger number of GCs are required to prove that the concurrent HER-2/neu positivity and high Ki-67 score are markers of worse prognosis.

摘要： 目的研究β-catenin、ki67及Her-2/Neu的蛋白表达与胃癌临床病理特征的关系,探讨分析β-catenin、ki67与Her-2/Neu蛋白表达、基因状态的相关性。方法采用免疫组化( SP)法检测101例胃癌标本中β-catenin、ki67及Her-2/Neu的蛋白表达,同时采用荧光原位杂交( FISH )技术对Her-2/Neu基因状态进行检测。结果β-catenin、ki67及Her-2/Neu的蛋白表达与胃癌临床病理特征关系密切：β-catenin、ki67与胃癌的分化程度、浸润深度、淋巴结转移具有显著相关性(P<0.05)；ki67与胃癌TNM分期具有显著相关性(P<0.05)；Her-2/Neu与胃癌的分化程度、TNM分期具有显著相关性(P<0.05),而与胃癌的浸润深度、淋巴结转移无显著相关性。 ki67蛋白表达与Her-2/Neu蛋白表达及基因扩增状态具有显著相关性( r蛋白=0.567,P<0.05；r基因=0.304,P<0.05)。结论联合检测β-catenin、ki67及Her-2/Neu可作为了解胃癌生物学行为、胃癌诊断、判断预后的可靠指标。 ki67可作为初筛Her-2/Neu基因状态的另一参考条件,对提高Her-2/Neu基因扩增检测效率、减少医用检测材料的浪费、指导临床靶向治疗可能有一定的意义。%Objective To study the relationship between the protein expression of β-catenin,ki67 and Her-2/Neu with the clinical pathologic characteristics of gastric cancer,and the correlation toβ-catenin and ki67 of the protein expression and gene conditions of Her-2/Neu. Methods Detected the protein expression of β-catenin,ki67 and Her-2/Neu by immunohistochemistry ( SP method) in 101 gastric cancer samples and the gene conditions of Her-2/Neu by fluorescence in situ hybridization ( FISH) . Results The protein expression of β-catenin,ki67 and Her-2/Neu had close relationship with the clinical pathologic characteristics of gastric cancer.β-catenin and ki67 had obvi-ous correlation to the differentiation, infiltration and lymphatic metastasis of the gastric cancer (P<0. 05). ki67 had close relationship with the TNM staging of gastric cancer ( P<0 . 05 ) . Her-2/Neu had close relationship with the differentiation and TNM staging of gastric cancer ( P<0 . 05 ) , but had no relationship with the infiltration and lymphatic metastasis of the gastric cancer. The protein expression of ki67 had obvious positive correlation to the pro-tein expression and gene amplification conditions of Her-2/Neu ( rprotein =0.567, P <0.05;rgene =0.304, P <0.05). Conclusion Association detection of β-catenin,ki67 and Her-2/Neu can be used as the reliable indexes in the process of understanding the biological behavior of gastric cancer,and gastric diagnosis and prognosis judge-ment and ki67 can be used as the reference in preliminary screening the gene amplification conditions of Her-2/Neu,which may have some significance in elevating the detection efficiency of Her-2/Neu gene amplification, re-ducing the detection material waste and guiding the clinical targeted therapy.

摘要： HER-2/neu over expression is associated with increased tumor aggressiveness, increased rates of recurrence, and increased mortality in node positive patients. It is amplified and/or over expressed in approximately 30% of female breast cancers. This study was to detect the relation between HER-2/neu over expression and steroid hormone receptor status. It was conducted at Cairo and Bani Suif university hospitals between February 2012 to February 2014. HER-2/neu over expression was found to be positive in thirteen patients (41%) out of the thirty two patients included in the study, more positive (52%) HER-2/neu was found among estrogen receptor (ER) positive patients, on the other hand, only 18% positive HER-2/neu was detected among ER negative patients. This difference was statistically significant (P < 0.03). The same outcome was with progesterone receptors (PR) and HER-2/neu with statistically significant difference also (P = 0.02). Conclusion: HER-2/neu over expression is strongly related to ER and PR, this was more evident in negative steroid receptors status. The failure of treatment in positive steroid receptors could be explained by HER-2/neu positivity.

摘要： AIM:To determine the frequency of HER2/neu protein overexpression in gastric(group A),small intestine(group B),and colorectal(group C)adenocarcinoma.METHODS:A descriptive,cross-sectional study was performed on 50 cases of gastrointestinal adenocarcinoma(stomach,small intestine,and colorectal);11from group A,8 from group B,and 31 from group C.The samples were grossed and processed in the pathology department,and sections were stained with HE(hematoxylin and eosin stain)for histopathological confirmation of malignancy(well-differentiated,moderately-differentiated,and poorly-differentiated).The confirmed samples were processed for immunomarker study of HER2/neu.RESULTS:HER2/neu protein overexpression was found in 33(66%)patients overall(P=0.000).Out of 33HER2/neu positive subjects,23(69.6%)were from group C,while the remaining 10(30%)were from group A.None of the patients from group B had positive HER2/neu protein overexpression.No protein overexpression or membrane staining in<10%tumor cells was observed in 17(34%)patients,which were labeled as score"0"and considered negative for HER2/neu protein overexpression.Faint/weak staining(in≥10%of tumors cells)were observed in 8(16%)patients and given the"1+"score.Similarly 13(26%)patients reported moderate staining(in≥10%tumor cells)and were thus labeled as"2+",and strong staining(in≥10%tumors cells),labeled as"3+",was observed in 12(24%)patients.Out of 50 patients,26(52%)were suffering from grade-Ⅱmalignancy,16(32%)from grade-Ⅰ,and 8(16%)from grade-Ⅲ.There was highly significant association between tumor grades and HER2/neu protein overexpression(P=0.0000).CONCLUSION:HER2/neu protein is credibly overexpressed in colon and gastric adenocarcinomas in immunohistochemistry.There is significant association between grade of tumor and HER2/neu protein overexpression.

摘要： 目的根据维汉不同种族乳腺癌组织免疫组化ER、PR、HER-2表达状态。方法2008年1月以后就诊于新疆巴州人民医ER、PR、HER-2院维汉乳腺癌患者184例,其中汉族患者155例，维吾尔族患者29例。首先研究不同种族和组织免疫组化之间的关系，然后再将ER、PR、HER-2表达作为筛选因素进一步剔除和ER、PR、HER-2表达状态无关的。通过筛选维汉种族中选择ER、PR、HER-2表达有关的临床免疫组化分界点。结果汉族人中ER、PR阳性表达比例65%，HER-2阳性表达比例60%；维吾尔族中ER、PR阳性表达比例40%， HER-2阳性表达比例35%。结论 ER、PR、HER-2与维汉中的乳腺癌不同，汉族人中ER/PR阳性率HER-2过度表达。

摘要： 目的:设计并制备显著激活细胞毒性T细胞(CTL)的高特异性HER-2/neu肽疫苗,并对其进行活性实验研究。方法:合成2种与MHC-Ⅰ类分子高亲和性的区段P、 P并对其进行修饰。建立BALB/c小鼠的乳腺癌模型,用上述多肽做疫苗,GM-CSF做佐剂,免疫小鼠,分别应用MTT法、ELISPOT法、颗粒酶释放法测定T细胞的增殖,T细胞分泌IFN-γ,CTL对肿瘤细胞的杀伤活性。结果:经修饰的HER-2/neu多肽疫苗可促进T细胞增殖,促进T细胞分泌IFN-γ及CTL杀伤乳腺癌细胞。结论:经修饰过的HER-2/neu多肽疫苗可显著激活细胞免疫,增加对乳腺癌细胞的杀伤作用。

摘要： 目的:设计并制备显著激活细胞毒性T细胞(CTL)的高特异性HER-2/neu肽疫苗,并对其进行活性实验研究。方法:合成2种与MHC-Ⅰ类分子高亲和性的区段P、 P并对其进行修饰。建立BALB/c小鼠的乳腺癌模型,用上述多肽做疫苗,GM-CSF做佐剂,免疫小鼠,分别应用MTT法、ELISPOT法、颗粒酶释放法测定T细胞的增殖,T细胞分泌IFN-γ,CTL对肿瘤细胞的杀伤活性。结果:经修饰的HER-2/neu多肽疫苗可促进T细胞增殖,促进T细胞分泌IFN-γ及CTL杀伤乳腺癌细胞。结论:经修饰过的HER-2/neu多肽疫苗可显著激活细胞免疫,增加对乳腺癌细胞的杀伤作用。

摘要： 目的:设计并制备显著激活细胞毒性T细胞(CTL)的高特异性HER-2/neu肽疫苗,并对其进行活性实验研究。方法:合成2种与MHC-Ⅰ类分子高亲和性的区段P、 P并对其进行修饰。建立BALB/c小鼠的乳腺癌模型,用上述多肽做疫苗,GM-CSF做佐剂,免疫小鼠,分别应用MTT法、ELISPOT法、颗粒酶释放法测定T细胞的增殖,T细胞分泌IFN-γ,CTL对肿瘤细胞的杀伤活性。结果:经修饰的HER-2/neu多肽疫苗可促进T细胞增殖,促进T细胞分泌IFN-γ及CTL杀伤乳腺癌细胞。结论:经修饰过的HER-2/neu多肽疫苗可显著激活细胞免疫,增加对乳腺癌细胞的杀伤作用。

摘要： 目的:设计并制备显著激活细胞毒性T细胞(CTL)的高特异性HER-2/neu肽疫苗,并对其进行活性实验研究。方法:合成2种与MHC-Ⅰ类分子高亲和性的区段P、 P并对其进行修饰。建立BALB/c小鼠的乳腺癌模型,用上述多肽做疫苗,GM-CSF做佐剂,免疫小鼠,分别应用MTT法、ELISPOT法、颗粒酶释放法测定T细胞的增殖,T细胞分泌IFN-γ,CTL对肿瘤细胞的杀伤活性。结果:经修饰的HER-2/neu多肽疫苗可促进T细胞增殖,促进T细胞分泌IFN-γ及CTL杀伤乳腺癌细胞。结论:经修饰过的HER-2/neu多肽疫苗可显著激活细胞免疫,增加对乳腺癌细胞的杀伤作用。

摘要： 本发明涉及调节唾液酸酶4(NEU4)的表达和/或功能的反义寡核苷酸，尤其是通过靶向唾液酸酶4(NEU4)的天然反义多核苷酸。本发明还涉及这些反义寡核苷酸的鉴定和它们在治疗NEU4表达相关的疾病和病症中的用途。

摘要： 本发明公开了适用于聚球藻UTEX 2973的Neu5Ac‑NanR诱导系统及构建方法与用途,诱导系统构建：构建载体pSI‑SPE‑PJ23119

摘要： 本发明公开一种基于LIP识别尿液中修饰UMOD的Neu5Gc检验尿路上皮癌的试剂盒，有捕获试剂、检测缓冲液及试纸，捕获试剂为生物素化偶联的七鳃鳗免疫蛋白LIP；检测缓冲液为50 mM Tris‑base，0.15 M NaCl，0.01%Tween‑20及7.5%BSA；试纸有底板，在底板上从左至右依次呈阶梯状地固接有加样垫、荧光微球偶联释放垫、硝酸纤维素膜和吸水垫，荧光微球偶联释放垫由铕荧光纳米颗粒与链酶亲和素SA和兔IgG的偶联液喷射在聚酯纤维上制备而成；硝酸纤维素膜上由左到右依次设置有由UMOD单抗构成的检测带和由羊抗兔IgG构成的参照带。

摘要： 本发明涉及特异性结合HER2/neu的抗体，并且尤其是HER2/neu的嵌合4D5抗体，所述4D5抗体与已知的4D5抗体相比具有减少的糖基化。本发明还涉及4D5抗体和包含它们的组合物用于下列疾病的诊断、预后和治疗的方法：例如，癌症、自身免疫疾病、炎性病患和传染病。

摘要： 本发明公开了一种荧光高效液相色谱检测发酵红肉制品中Neu5Gc的方法，包括：配制Neu5Gc标准品溶液；Neu5Gc标准曲线绘制；发酵红肉制品样品溶液的制备；柱前衍生；荧光高效液相色谱条件；样品中Neu5Gc的含量测定。本发明检测结果准确、重复性好，检测的特异性和灵敏度高，能有效降低检测时间，提高检测效率、成本低，毒性小。

摘要： 本发明涉及调节唾液酸酶4(NEU4)的表达和/或功能的反义寡核苷酸，尤其是通过靶向唾液酸酶4(NEU4)的天然反义多核苷酸。本发明还涉及这些反义寡核苷酸的鉴定和它们在治疗NEU4表达相关的疾病和病症中的用途。

摘要： 本发明公开了P‑3Fax‑Neu5Ac的新的药物用途。P‑3Fax‑Neu5Ac可以在细胞中显著降低不溶性tau聚集物，并在小鼠脑内有效阻止tau病理的产生和传播，能够用于制备治疗阿尔茨海默病药物。

摘要： 本发明公开了一种唾液酸Neu5Ac衍生物及其制备方法和应用，衍生物结构如下所示：其中，R1选自羟基、甲氧基或取代的甲氧基；R2选自乙酰氨基、取代的乙酰氨基、苯甲酰氨基、取代的苯甲酰氨基、烷氧羰酰胺基、三氮唑基或取代的三氮唑基；R3选自羟基、甲氧基、取代的甲氧基、乙酰氨基、取代的乙酰氨基、磺酰胺基、取代的磺酰胺基或磷酰胺基；A为或‑(CH2)m‑R4，其中，R4选自氨基、巯基或叠氮基；n选自0,1,2,3,4,5,6,7；m选自2,3,4,5,6,7,8,9,10。本发明提供的衍生物既能高亲和结合新冠病毒表面S蛋白，又通过衍生功能侧链赋予其更广泛的应用，包括检测新冠病毒、治疗新冠肺炎等。

摘要： 本发明涉及一种由低成本底物N‑乙酰‑D‑葡萄糖胺(GlcNAc)、丙酮酸盐、胞苷和多磷酸盐在与一组任选固定或任选共固定的酶在单一反应混合物中产生胞苷5′‑单磷酸‑N‑乙酰‑神经氨酸(CMP‑Neu5Ac，1)的方法，所述酶包括N‑酰基葡萄糖胺2‑差向异构酶(AGE)、N‑乙酰神经氨酸裂解酶(NAL)、N‑酰基神经氨酸胞苷酰转移酶(CSS)、尿苷激酶(UDK)、单磷酸尿苷激酶和多磷酸激酶3(PPK3)。此外，所述方法可适于产生Neu5酰化的即唾液酸化的生物分子和生物分子，其包括糖、肽、蛋白质、糖肽、糖蛋白、糖脂、聚糖、抗体和糖缀合物，特别是抗体药物缀合物和碳水化合物缀合疫苗或类黄酮。

摘要： 本发明公开一种基于LIP识别尿液中修饰UMOD的Neu5Gc检验尿路上皮癌的试剂盒，有捕获试剂、检测缓冲液及试纸，捕获试剂为生物素化偶联的七鳃鳗免疫蛋白LIP；检测缓冲液为50 mM Tris‑base，0.15 M NaCl，0.01% Tween‑20及7.5% BSA；试纸有底板，在底板上从左至右依次呈阶梯状地固接有加样垫、荧光微球偶联释放垫、硝酸纤维素膜和吸水垫，荧光微球偶联释放垫由铕荧光纳米颗粒与链酶亲和素SA和兔IgG的偶联液喷射在聚酯纤维上制备而成；硝酸纤维素膜上由左到右依次设置有由UMOD单抗构成的检测带和由羊抗兔IgG构成的参照带。